James P. Allison

Oncology · 2001–2023

A researcher in the Science corpus: 42 papers; trusts 19 researchers and is trusted by 42 researchers here, as inferred from the citation graph.

Subfields

Whom James P. Allison trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. G. Freeman
  3. C. Robert
  4. Sergio A. Quezada
  5. K. Peggs
  6. F. Hodi
  7. Arlene H. Sharpe
  8. J. Wolchok
  9. S. Rosenberg

Who trusts James P. Allison overall

  1. Hazem E. Ghoneim
  2. S. Farkona
  3. Lieping Chen
  4. Padmanee Sharma
  5. Yuanyuan Zhang
  6. Chunbai He
  7. S. Wei
  8. C. Blank
  9. Yiping Fan
  10. Arlene H. Sharpe

Papers from James P. Allison's perspective

Ordered by how strongly the researchers James P. Allison trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  4. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
  5. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
  6. Tumor-specific Th17-polarized cells eradicate large established melanoma. (Blood)
  7. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
  8. Modulation of tryptophan catabolism by regulatory T cells (Nature Immunology)
  9. An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
  10. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)

Their papers